Abstract: The present disclosure provides a system for generating interference-mitigated images of a scene within a sensed field of view. The system comprises a sensor array comprising a plurality of sensor elements configured to transmit a waveform and receive corresponding echo and interference signals. The system comprises an adaptation device configured to receive data acquired by the sensor array, estimate or determine characteristics of interference within the received data, and mitigate the interference to generate interference-mitigated data. The system comprises a processor configured to reconstruct one-dimensional, two-dimensional, or three-dimensional images of the sensed field of view by performing Fresnel-based imaging operations on the interference-mitigated data. The data acquired by the sensor array is from transmission of a single pulse or a plurality of pulses, or corresponds to motion of the sensor array.

Abstract: The present disclosure provides an in vitro mammalian cell that is genetically modified to provide for enhanced production of adeno-associated virus (AAV) virions. The mammalian cells can be used to produce AAV virions, e.g., recombinant AAV virions that include a heterologous nucleic acid encoding a gene product; the present disclosure thus provides methods for producing an AAV virion, which may be a recombinant AAV virion.

Abstract: Polycystic ovary syndrome (PCOS) is characterized by elevated levels of androgens, cysts in the ovaries, and irregular periods. Women with PCOS present with additional symptoms, including hirsutism, alopecia, acne, infertility, weight gain, fatigue, depression and mood changes. The present disclosure provides new compounds, salts, compositions and uses thereof in the treatment of PCOS due to elevated adrenal androgens. Further, the present disclosure provides methods for treating PCOS due to elevated adrenal androgens.

Abstract: Polycystic ovary syndrome (PCOS) is characterized by elevated levels of androgens, cysts in the ovaries, and irregular periods. Women with PCOS present with additional symptoms, including hirsutism, alopecia, acne, infertility, weight gain, fatigue, depression and mood changes. The present disclosure provides new compounds, salts, compositions and uses thereof in the treatment of PCOS due to elevated adrenal androgens. Further, the present disclosure provides methods for treating PCOS due to elevated adrenal androgens.

Abstract: Described herein are crystalline composition, methods of making such crystalline composition, pharmaceutical compositions and medicaments comprising such crystalline composition, and methods of using such crystalline composition in the treatment of conditions, diseases, or disorders that would benefit from modulation of Corticotropin-releasing hormone receptor 1 (CRF1).

Abstract: The present invention provides for cross-neutralizing SARS-COV2 antibodies. The antibodies can be used to treat SARS-CoV2 and variants thereof.

Abstract: Patients with congenital adrenal hyperplasia (CAH) need adequate care and treatment in order to lead normal lives. Hence, there is a need for new methods of treating CAH. This disclosure provides new compounds, salts, compositions and uses thereof in the treatment of CAH.

Abstract: Described herein are crystalline composition, methods of making such crystalline composition, pharmaceutical compositions and medicaments comprising such crystalline composition, and methods of using such crystalline composition in the treatment of conditions, diseases, or disorders that would benefit from modulation of Corticotropin-releasing hormone receptor 1 (CRF1).

Abstract: Polycystic ovary syndrome (PCOS) is characterized by elevated levels of androgens, cysts in the ovaries, and irregular periods. Women with PCOS present with additional symptoms, including hirsutism, alopecia, acne, infertility, weight gain, fatigue, depression and mood changes. The present disclosure provides new compounds, salts, compositions and uses thereof in the treatment of PCOS due to elevated adrenal androgens. Further, the present disclosure provides methods for treating PCOS due to elevated adrenal androgens.

Abstract: Polycystic ovary syndrome (PCOS) is characterized by elevated levels of androgens, cysts in the ovaries, and irregular periods. Women with PCOS present with additional symptoms, including hirsutism, alopecia, acne, infertility, weight gain, fatigue, depression and mood changes. The present disclosure provides new compounds, salts, compositions and uses thereof in the treatment of PCOS due to elevated adrenal androgens. Further, the present disclosure provides methods for treating PCOS due to elevated adrenal androgens.

Abstract: Polycystic ovary syndrome (PCOS) is characterized by elevated levels of androgens, cysts in the ovaries, and irregular periods. Women with PCOS present with additional symptoms, including hirsutism, alopecia, acne, infertility, weight gain, fatigue, depression and mood changes. The present disclosure provides new compounds, salts, compositions and uses thereof in the treatment of PCOS due to elevated adrenal androgens. Further, the present disclosure provides methods for treating PCOS due to elevated adrenal androgens.

Abstract: Described herein are crystalline composition comprising a Corticotropin-releasing hormone receptor 1 (CRF1) antagonist, such as Compound 1: methods of making such crystalline composition, pharmaceutical compositions and medicaments comprising such crystalline composition, and methods of using such crystalline composition in the treatment of conditions, diseases, or disorders that would benefit from modulation of CRF.

Abstract: Described herein are crystalline composition comprising a Corticotropin-releasing hormone receptor 1 (CRF1) antagonist, such as Compound 1: methods of making such crystalline composition, pharmaceutical compositions and medicaments comprising such crystallin composition, and methods of using such crystalline composition in the treatment of conditions, diseases, or disorders that would benefit from modulation of CRF.

Abstract: A computing system receives decrypts learned parameters of a computer-implemented predictive model stored in a computer-readable, non-volatile data store upon instantiation of a model process in volatile memory of the computing system. The predictive model is parameterized by learned parameters that are based upon private data of a user, wherein the learned parameters of the predictive model have been encrypted subsequent to training of the predictive model based upon the private data of the user. The computing system receives a request for a prediction associated with the user. Upon authorizing the request, the computing identifies the predictive model. The computing system, by way of the model process, generates the prediction based upon the request and the predictive model. The computing system outputs the prediction to a computing device associated with the user.

Abstract: The present disclosure provides an in vitro mammalian cell that is genetically modified to provide for enhanced production of adeno-associated virus (AAV) virions. The mammalian cells can be used to produce AAV virions, e.g., recombinant AAV virions that include a heterologous nucleic acid encoding a gene product; the present disclosure thus provides methods for producing an AAV virion, which may be a recombinant AAV virion.

Abstract: Patients with congenital adrenal hyperplasia (CAH) need adequate care and treatment in order to lead normal lives. Hence, there is a need for new methods of treating CAH. This disclosure provides new compounds, salts, compositions and uses thereof in the treatment of CAH.

Abstract: Techniques for efficient medical appointment scheduling are described. In an example, a method of facilitating access between a patient endpoint system and a healthcare provider computer system includes: receiving, at a management computer system through a network, healthcare provider information from the healthcare provider computer; storing the healthcare provider information in a database along with a collection of healthcare provider information from a plurality of other healthcare provider computer systems, the healthcare provider information including appointment availability information; providing, from the management computer to the patient endpoint system, an interface to the database to retrieving the healthcare provider information; and providing, from the patient endpoint system to the healthcare provider computer system, a request for an appointment based on the appointment availability information retrieved by the patient endpoint system from the database.

Abstract: A computing system receives decrypts learned parameters of a computer-implemented predictive model stored in a computer-readable, non-volatile data store upon instantiation of a model process in volatile memory of the computing system. The predictive model is parameterized by learned parameters that are based upon private data of a user, wherein the learned parameters of the predictive model have been encrypted subsequent to training of the predictive model based upon the private data of the user. The computing system receives a request for a prediction associated with the user. Upon authorizing the request, the computing identifies the predictive model. The computing system, by way of the model process, generates the prediction based upon the request and the predictive model. The computing system outputs the prediction to a computing device associated with the user.

Abstract: The present disclosure provides a gene delivery system comprising: a) an R2 retrotransposon R2 polypeptide, or a first nucleic acid comprising a nucleotide sequence encoding the R2 polypeptide; and b) a nucleic acid comprising a heterologous nucleotide sequence encoding one or more heterologous gene products, where the heterologous nucleotide sequence is flanked by an R2 retrotransposon 3? untranslated region (UTR) and an R2 retrotransposon 5? UTR, and where the heterologous nucleotide sequence has a length of at least 200 nucleotides. The present disclosure provides a method of delivering one or more gene products of interest to a eukaryotic cell, the method comprising contacting the cell with the gene delivery vehicle system.

Abstract: A method of charging a cell of a battery includes the steps of: applying a test current to an input terminal of the battery; measuring a voltage output, wherein the voltage output is comprised of a voltage of the cell and a voltage drop, induced by the test current, across an internal impedance of the battery; and applying a charging current to the input terminal of the battery if the measured voltage output is higher than a predetermined voltage, wherein the charging current is greater than the test current.